The US Food and Drug Administration (FDA) has accepted for review US-based biopharmaceutical firm NPS Pharmaceuticals' supplemental new drug application (sNDA) for Gattex (teduglutide [rDNA origin]) for injection. In the US, Gattex is ...
Tags: FDA, biopharmaceutical
Romaco technologies will showcase its new Macofar LF 200 ST sterile liquid filler and Noack 960 Blister System at the P-MEC in Mumbai, India, which will be held between 3 to 5 December 2013. Macofar LF 200 ST will be used to fill ...
Antares Pharma, a provider of self-injection drug delivery technology, has received a US Patent, entitled 'Prefilled Syringe Jet Injector', which will help in protecting its auto injector technology and product pipeline including the VIBEX ...
Biopharmaceutical firm Cubist Pharmaceuticals is voluntarily recalling four lots of Cubicin (daptomycin for injection) 500mg in 50ml single use vials in the US primarily due to presence of glass particulates. The company said that no ...
Tags: Cubicin Injection, Cubist
Clearance, an AngioDynamics company, has received the US Food and Drug Administration (FDA) 510(k) clearance for its BioFlo Port with Endexo technology, Clearance to the accumulation of platelets and thrombus. The BioFlo Port is a ...
American Regent, a subsidiary of a Daiichi Sankyo Group Company named Luitpold Pharmaceuticals, has won USFDA approval for Injectafer (ferric carboxymaltose injection) for the treatment of iron deficiency anemia (IDA). A parenteral iron ...
Tags: Iron Deficiency Anemia, Medicine
The US Food and Drug Administration (FDA) has accepted to review Antares Pharma's new drug application (NDA) of OTREXUP, designed for the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis. OTREXUP ...
US-based Smiths Medical has gained US marketing rights for its CADD-Solis variable infusion profile (VIP) ambulatory infusion system, following the US Food and Drug Administration (FDA) approval. The multi-therapy infusion system, which ...
Tags: FDA, therapy infusion system, Medical
On Feb. 13-14, 2013, the healthcare industry's major players will convene at the 12th edition of Pharmapack Europe at Grande Halle de la Villette (Paris). More than 3,000 visitors from four continents and more than 290 international ...
Tags: Pharmaceutical Packaging, Packaging Experts, Key Issues
A. Hopf, a developer of injection moulding solutions, has launched new 3-way stopcocks and Y-connectors, designed for use in enteral feeding systems. Made with Eastman Chemical Company's Tritan copolyester, the new stopcocks and ...
Tags: A.Hopf, stopcocks, Y-connectors, enteral feeding systems
DISCLAIMER: UBM Canon is the parent company of Packaging Digest. The 12th edition of Pharmapack Europe, Feb. 13-14, 2013, Grande Halle de la Villette (Paris), will welcome more than 3,000 visitors from all over the globe and around 280 ...
Tags: UBM Canon, Packaging, Pharma packaging
Contract pharmaceutical company in the US Patheon has sold its global secondary clinical packaging and clinical distribution services business to Bellwyck Packaging Solutions for an undisclosed sum. Patheon chief executive officer James ...
Tags: Patheon, clinical packaging, clinical distribution, Canadian company
Drugmaker in Bangladesh Square Pharmaceuticals has contracted Spain-based Telstar to build two new pharmaceutical plants, an oral solids facility and parenteral drugs making facility for the company. The 32,000m2 solid dose facility will ...
Tags: Square Pharmaceuticals, pharmaceutical plants, oral solids facility
Takeda Pharmaceutical Company and NPS Pharmaceuticals have announced positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Teduglutide (Revestive) for patients with short bowel syndrome (SBS). Teduglutide, ...
Tags: short bowel syndrome, teduglutide, glucagon-like peptide 2
Toronto-based Bellwyck Packaging Solutions has entered into an agreement to buy Patheon's global secondary clinical packaging and clinical distribution services business for an undisclosed sum. Patheon chief executive officer James Mullen ...